A 15-year follow-up of a study, known as SWOG S0016, has been reported, focusing on first-line CHOP-based therapy in advanced-stage follicular lymphoma. The study's results have been interpreted as suggesting that follicular lymphoma may be curable, although the implications for treatment practices are still being considered. The study's findings are being analyzed in the context of other treatment approaches, including radioimmunotherapy and rituximab-based therapy.